214045-84-8

Usage

Uses

Used in Pharmaceutical Industry:
6-Fluoro-3,4-dihydro-2H-isoquinolin-1-one is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. The presence of a fluorine atom in its structure may enhance the drug properties, such as increasing stability, bioavailability, or improving the drug's interaction with biological targets.
Used in Scientific Research:
6-Fluoro-3,4-dihydro-2H-isoquinolin-1-one serves as a valuable compound in scientific research, particularly in the fields of organic chemistry and medicinal chemistry. It may be used to study the effects of fluorination on the chemical properties and reactivity of isoquinoline derivatives, as well as to explore its potential as a precursor for the development of new drugs or drug candidates.
Used in Industrial Applications:
Although specific applications are not well-documented, 6-Fluoro-3,4-dihydro-2H-isoquinolin-1-one may have potential uses in various industrial processes, such as the synthesis of specialty chemicals, materials, or dyes. 6-FLUORO-3,4-DIHYDRO-2H-ISOQUINOLIN-1-ONE's unique structure and properties could be harnessed for the development of novel products or to improve existing ones.
Note: Due to the limited information available on 6-Fluoro-3,4-dihydro-2H-isoquinolin-1-one, the above uses are based on the general properties of isoquinoline derivatives and the potential benefits of fluorination in chemical compounds. Further research and investigation are necessary to fully understand the compound's applications and potential.

Upstream product

• 1403029-54-8 2-3-fluorophenylethylcarbamic acid methyl ester 
• 102422-57-1 1-Fluoro-3-(2-isocyanato-ethyl)-benzene 
• 404-70-6 2-(3-Fluorophenyl)ethylamine 
• 20595-30-6 3-fluorocinnamic acid 
• 458-45-7 3-(3-fluorophenyl)propionic acid 
• 456-48-4 3-Fluorobenzaldehyde 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 700-84-5 5-fluoro-1-indanone 

Downstream Products

• 888226-98-0 6-(4-methyl-piperazin-1-yl)-3,4-dihydro-2H-isoquinolin-1-one 
• 888226-97-9 6-(4-benzyl-piperazin-1-yl)-3,4-dihydro-2H-isoquinolin-1-one 
• 888227-01-8 6-(4-benzyl-piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline 
• 352557-07-4 6-hydrazino-3,4-dihydroisoquinolin-1(2H)-one 
• 214190-33-7 2-N-benzyl-6-fluoro-3,4-dihydro-2H-isoquinolin-1-one 
• 224161-37-9 6-fluoro-1,2,3,4-tetrahydroisoquinoline 
• 214045-85-9 6-fluoro-1,2-dihydroisoquinolin-1-one 
• 1178884-33-7 6-dimethylamino-3,4-dihydro-2H-isoquinolin-1-one 
• 1256961-27-9 6-benzylamino-3,4-dihydro-2H-isoquinolin-1-one 
• 1309955-33-6 USC-G₄₀₁ 
• 1178884-09-7 6-(dimethylamino)-2-(2-(hydroxymethyl)-3-(1-methyl-5-(5-(morpholine-4-carbonyl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1242156-99-5 C₁₈H₁₇BrN₂O₂ 
• 1198765-28-4 C₃₄H₃₄N₆O₅ 
• 1462328-86-4 2-(3-chloro-2-(hydroxymethyl)phenyl)-6-(dimethylamino)-3,4-dihydroisoquinolin-1(2H)-one 

Relevant academic research and scientific papers

Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model

A hallmark of cancer is unbridled proliferation that can result in increased demand for de novo synthesis of purine and pyrimidine bases required for DNA and RNA biosynthesis. These synthetic pathways are frequently upregulated in cancer and involve various folate-dependent enzymes. Antifolates have a proven record as clinically used oncolytic agents. Our recent research efforts have produced LSN 3213128 (compound 28a), a novel, selective, nonclassical, orally bioavailable antifolate with potent and specific inhibitory activity for aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICARFT), an enzyme in the purine biosynthetic pathway. Inhibition of AICARFT with compound 28a results in dramatic elevation of 5-aminoimidazole 4-carboxamide ribonucleotide (ZMP) and growth inhibition in NCI-H460 and MDA-MB-231met2 cancer cell lines. Treatment with this inhibitor in a murine based xenograft model of triple negative breast cancer (TNBC) resulted in tumor growth inhibition.

Synthesis and evaluation of tetrahydroisoquinoline-benzimidazole hybrids as multifunctional agents for the treatment of Alzheimer's disease

A novel series of tetrahydroisoquinoline-benzimidazole hybrids have been designed and synthesized as multifunctional agents against Alzheimer's disease (AD). These compounds were evaluated for their inhibition of neuroinflammation and human β-secretase (hBACE1), and neuroprotective activity. Among them, compound BD3 possessed significant anti-neuroinflammatory activity (IC50 = 5.07 μM against nitric oxide production) through inhibiting the expression and secretion of proinflammatory cytokines in BV2 cells. Compound BD3 also exhibited moderate hBACE1 inhibitory activity (65.7% inhibition at 20 μM) and potent neuroprotective effect by increasing GSH level and reducing ROS production (91.8% cell viability at 5 μM). Parallel artificial membrane permeation assay demonstrated that BD3 could cross the blood-brain barrier (BBB). Thus, this study demonstrates that the compounds with tetrahydroisoquinoline-benzimidazole scaffold are potential anti-AD agents, and they are worth for the further development.

SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME

The present invention includes substituted arylmethyl ureas and heteroarylmethyl-ureas, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient.

Intramolecular Reductive Cyclization of o-Nitroarenes via Biradical Recombination

A visible-light-induced/thiourea-mediated intramolecular cyclization of o-nitroarenes under mild conditions is realized for the first time, which provides an efficient and environmentally friendly way to access pharmaceutical relevant quinazolinone derivatives. The reaction can be easily extended to gram level by using a continuous-flow setup with high efficiency. Mechanistic investigation including control experiments, transient fluorescence, UV-vis spectra, and DFT calculations suggests that the formation of active biradical intermediates via intramolecular single electron transfer (SET) is key stage in the catalytic cycle.

Metal-Free Synthesis of Polycyclic Quinazolinones Enabled by a (NH4)2S2O8-Promoted Intramolecular Oxidative Cyclization

An efficient metal-free, (NH4)2S2O8 mediated intramolecular oxidative cyclization for the construction of polycyclic heterocycles was disclosed. A series of polycyclic quinazolinone derivatives with good functional group tolerance were obtained in high yields. The natural products tryptanthrin and rutaecarpine, as well as their derivatives, were easily synthesized by this strategy. A preliminary mechanism study suggested the carbon-centered radical was involved in the catalytic cycle.

Cyclic-fused ASK1 inhibitor and application thereof

The invention relates to a cyclic-fused ASK1 inhibitor and application thereof, and particularly to a compound shown in formula (I), a pharmacologically acceptable salt and ester thereof, and a stereisomer thereof. The invention further relates to a preparation method of the compound, a pharmaceutic preparation and a pharmaceutical composition containing the compound. The compound of the inventionis capable of effectively inhibiting phosphorylation of amino acid of ASK1, and inhibiting the activation of the ASK1, thereby can be used for treating and/or preventing ASK1-mediated diseases and related diseases.

Light-Driven Intramolecular C?N Cross-Coupling via a Long-Lived Photoactive Photoisomer Complex

Reported herein is a visible-light-driven intramolecular C?N cross-coupling reaction under mild reaction conditions (metal- and photocatalyst-free, at room temperature) via a long-lived photoactive photoisomer complex. This strategy was used to rapidly prepare the N-substituted polycyclic quinazolinone derivatives with a broad substrate scope (>50 examples) and further exploited to synthesize the natural products tryptanthrin, rutaecarpine, and their analogues. The success of gram-scale synthesis and solar-driven transformation, as well as promising tumor-suppressing biological activity, proves the potential of this strategy for practical applications. Mechanistic investigations, including control experiments, DFT calculations, UV-vis spectroscopy, EPR, and X-ray single-crystal structure of the key intermediate, provides insight into the mechanism.

A multi-functional the anti-ahl tribulus sea is silent disease of the benzimidazole derivatives and its preparation method and application

The invention provides a multi-functional anti-the erzierzi sea is silent disease of benzimidazole derivative and its preparation method and application. Said styrene and imidazole derivatives having a structure of formula (I) is shown; Wherein formula (I) R in1 Is H, C1 - C5 alkyl, C1 - C5 alkoxy, halogen base, hydroxy or amino, X is C or N atom. The invention is based on the fragment assembly of the lead compound discovery method, through the tetrahydroisoquinoline and benzimidazole two fragment assembly, design is a new skeleton molecule, and synthesizing a series of benzimidazole derivatives. The present invention provides a benzimidazole derivative with antineuritic activity at the same time, BACE1 inhibitory activity and cell protective activity, and can penetrate the blood-brain barrier; at the same time the benzimidazole derivatives for the preparation of simple, low cost, stable structure, convenient for storage, can be used as a treating [...] of one kind of precursor compound.

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS

1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.